

# Daniel F Hayes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914311/publications.pdf>

Version: 2024-02-01

138  
papers

23,435  
citations

28274

55  
h-index

12597

132  
g-index

142  
all docs

142  
docs citations

142  
times ranked

25263  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 781-791.	27.0	4,124
2	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
3	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	6.3	1,505
4	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	27.0	1,052
5	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. <i>Clinical Cancer Research</i> , 2006, 12, 4218-4224.	7.0	937
6	Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1446-1452.	6.3	899
7	2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. <i>Journal of Clinical Oncology</i> , 2001, 19, 1865-1878.	1.6	770
8	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 907-922.	2.5	697
9	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	27.8	685
10	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	1.6	683
11	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	1.6	673
12	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	1.6	668
13	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489.	1.6	543
14	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1496-1506.	27.0	531
15	An International Ki67 Reproducibility Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1897-1906.	6.3	498
16	Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. <i>Nature Nanotechnology</i> , 2013, 8, 735-741.	31.5	487
17	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	27.0	363
18	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 435-444.	27.0	352

#	ARTICLE	IF	CITATIONS
19	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349
20	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	6.3	319
21	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2695-2704.	1.6	279
22	Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 365-372.	2.5	200
23	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.	12.8	196
24	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	5.5	195
25	Prognostic factors in breast cancer: current and new predictors of metastasis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 375-392.	2.7	184
26	Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and CellSave blood collection tubes. <i>Clinical Biochemistry</i> , 2016, 49, 1354-1360.	1.9	175
27	Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting. <i>Journal of Clinical Oncology</i> , 2012, 30, 4223-4232.	1.6	173
28	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	7.0	170
29	Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer. <i>Oncologist</i> , 2006, 11, 541-552.	3.7	132
30	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	2.5	120
31	c-erbB-2 in breast cancer: Development of a clinically useful marker. <i>Seminars in Oncology</i> , 2002, 29, 231-245.	2.2	119
32	Breaking a Vicious Cycle. <i>Science Translational Medicine</i> , 2013, 5, 196cm6.	12.4	112
33	Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2487-2498.	7.0	112
34	Biomarker validation and testing. <i>Molecular Oncology</i> , 2015, 9, 960-966.	4.6	109
35	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	5.2	109
36	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2710-2717.	1.6	108

#	ARTICLE	IF	CITATIONS
37	Biospecimen Reporting for Improved Study Quality. <i>Biopreservation and Biobanking</i> , 2011, 9, 57-70.	1.0	106
38	Biomarker studies: a call for a comprehensive biomarker study registry. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 171-176.	27.6	106
39	Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?. <i>Clinical Cancer Research</i> , 2008, 14, 3646-3650.	7.0	104
40	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5864-5875.	7.0	99
41	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1226-1234.	27.0	95
42	Prognostic and predictive factors revisited. <i>Breast</i> , 2005, 14, 493-499.	2.2	93
43	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. <i>Cancer Research</i> , 2018, 78, 1110-1122.	0.9	85
44	Follow-up of Patients with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2505-2513.	27.0	83
45	Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. <i>Molecular Oncology</i> , 2013, 7, 680-692.	4.6	82
46	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. <i>Nature Communications</i> , 2019, 10, 1478.	12.8	80
47	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	7.0	78
48	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. <i>Modern Pathology</i> , 2019, 32, 59-69.	5.5	78
49	Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. <i>Breast Cancer Research and Treatment</i> , 1998, 52, 239-259.	2.5	74
50	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	2.9	74
51	Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 235-258.	1.6	69
52	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1324-1331.	4.1	65
53	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 525-533.	7.1	65
54	Pretreatment worry and neurocognitive responses in women with breast cancer.. <i>Health Psychology</i> , 2014, 33, 222-231.	1.6	62

#	ARTICLE	IF	CITATIONS
55	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	6.3	62
56	Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!. <i>Journal of Clinical Oncology</i> , 2012, 30, 1264-1267.	1.6	59
57	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. <i>British Journal of Cancer</i> , 2020, 122, 801-811.	6.4	52
58	Bevacizumab Treatment for Solid Tumors. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 506.	7.4	51
59	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	7.1	51
60	Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. <i>Journal of Clinical Oncology</i> , 2021, 39, 238-248.	1.6	49
61	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	6.3	48
62	Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju034-dju034.	6.3	47
63	Molecular Testing in Breast Cancer. <i>Annual Review of Medicine</i> , 2014, 65, 95-110.	12.2	47
64	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. <i>Clinical Cancer Research</i> , 2019, 25, 6089-6097.	7.0	46
65	Angiogenesis as targeted breast cancer therapy. <i>Breast</i> , 2007, 16, 17-19.	2.2	45
66	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 29.	5.2	45
67	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5860-5872.	7.0	44
68	Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. <i>Molecular Oncology</i> , 2016, 10, 1078-1085.	4.6	43
69	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 384-389.	2.5	42
70	Disseminated breast tumour cells: biological and clinical meaning. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 129-131.	27.6	42
71	American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. <i>Journal of Clinical Oncology</i> , 2017, 35, 2576-2579.	1.6	41
72	Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i> -associated breast cancer (SWOG S1416).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1001-1001.	1.6	40

#	ARTICLE	IF	CITATIONS
73	Circulating Tumor Cells. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 95, 95-112.	1.7	37
74	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	5.2	36
75	Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 36-39.	2.1	35
76	Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 87-95.	2.5	35
77	Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 589-595.	2.5	34
78	Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 657-666.	2.5	34
79	The role of c-erbB-2 as a predictive factor in breast cancer. <i>Breast Cancer</i> , 2001, 8, 171-183.	2.9	32
80	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , 2015, 9, 1868-1876.	4.6	29
81	Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3796-3802.	1.6	29
82	Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitor-Treated Women With Early-Stage Breast Cancer. <i>Journal of Pain</i> , 2014, 15, 468-475.	1.4	28
83	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 263-273.	2.5	27
84	Circulating Tumor Markers in Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 653-674.	2.2	27
85	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. <i>PLoS ONE</i> , 2021, 16, e0260124.	2.5	26
86	Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey device for CTC enrichment. <i>Lab on A Chip</i> , 2021, 21, 3559-3572.	6.0	25
87	Tamoxifen: Dr. Jekyll and Mr. Hyde?. <i>Journal of the National Cancer Institute</i> , 2004, 96, 895-897.	6.3	24
88	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	3.5	24
89	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 163-172.	2.5	23
90	Contribution of biomarkers to personalized medicine. <i>Breast Cancer Research</i> , 2010, 12, S3.	5.0	18

#	ARTICLE	IF	CITATIONS
91	OMICS-based personalized oncology: if it is worth doing, it is worth doing well!. BMC Medicine, 2013, 11, 221.	5.5	18
92	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. Journal of Clinical Oncology, 2018, 36, 617-623.	1.6	18
93	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	5.5	18
94	Markers of increased risk for failure of adjuvant therapies. Breast, 2003, 12, 543-549.	2.2	17
95	Precision Medicine and Testing for Tumor Biomarkers—Are All Tests Born Equal?. JAMA Oncology, 2018, 4, 773.	7.1	17
96	Genome Medicine in Cancer: What's in a Name?. Cancer Research, 2015, 75, 1930-1935.	0.9	16
97	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. Npj Breast Cancer, 2021, 7, 77.	5.2	16
98	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
99	Steady Progress against HER2-Positive Breast Cancer. New England Journal of Medicine, 2011, 365, 1336-1338.	27.0	14
100	Innovations in American Society of Clinical Oncology Practice Guideline Development. Journal of Clinical Oncology, 2016, 34, 3213-3220.	1.6	14
101	From genome to bedside: Are we lost in translation?. Breast, 2013, 22, S22-S26.	2.2	13
102	Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. Breast, 2015, 24, S6-S10.	2.2	13
103	Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. British Journal of Clinical Pharmacology, 2016, 81, 1134-1141.	2.4	13
104	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
105	Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. Clinical Breast Cancer, 2017, 17, 350-355.e4.	2.4	10
106	Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Research and Treatment, 2017, 164, 411-419.	2.5	10
107	Ki67 as a Companion Diagnostic: Good or Bad News?. Journal of Clinical Oncology, 2022, 40, 3796-3799.	1.6	10
108	ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiological Genomics, 2016, 48, 688-698.	2.3	9



#	ARTICLE	IF	CITATIONS
109	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123.	7.0	9
110	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 453-461.	2.5	8
111	Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 147-160.	1.8	8
112	Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. <i>Journal of Clinical Oncology</i> , 2022, 40, 1721-1731.	1.6	8
113	Serial monitoring of genomic alterations in circulating tumor cells of ERâ€“positive/HER2â€“negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2022, 16, 1969-1985.	4.6	8
114	Markers of endocrine sensitivity. <i>Breast Cancer Research</i> , 2008, 10, S18.	5.0	7
115	Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 292-296.	3.8	7
116	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 659-668.	2.5	7
117	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. <i>Pharmacogenomics</i> , 2019, 20, 571-580.	1.3	7
118	Osteonecrosis of the jaw risk factors in bisphosphonateâ€“treated patients with metastatic cancer. <i>Oral Diseases</i> , 2022, 28, 193-201.	3.0	7
119	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. <i>Npj Breast Cancer</i> , 2022, 8, 31.	5.2	7
120	Is Breast Cancer a Curable Disease?. <i>Journal of Oncology Practice</i> , 2016, 12, 13-16.	2.5	6
121	Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?. <i>Breast</i> , 2009, 18, S131-S134.	2.2	4
122	Response to Zhang and Yang. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1597-1598.	6.3	4
123	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 116-123.	1.5	4
124	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptorâ€“positive Breast Cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2022, 28, 611-617.	7.0	4
125	Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 297-303.	2.5	3
126	Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1559-1560.	6.3	2



#	ARTICLE	IF	CITATIONS
127	Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	2
128	Cyclin E as a prognostic factor: What is the question?. <i>Cell Cycle</i> , 2009, 8, 965-965.	2.6	1
129	Cost-effective analyses in Breast Cancer Research and Treatment. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 221-222.	2.5	1
130	Disease related indicators for a proper choice of adjuvant treatments. <i>Breast</i> , 2011, 20, S162-S164.	2.2	1
131	Reply to F.-C. Bidard et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1623-1623.	1.6	1
132	Predictive and prognostic markers in cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 130-2.	0.3	1
133	RESPONSE: Re: Playing the Old Piano: Another Tune for Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2004, 96, 557-557.	6.3	0
134	Adjuvant Systemic Therapy for Elderly Women with Breast Cancer. <i>Women's Health</i> , 2006, 2, 75-87.	1.5	0
135	Delivery of Personalized Medicine With Precision. <i>JCO Precision Oncology</i> , 2017, 1, 1-3.	3.0	0
136	Learning From Our Patients. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-3.	2.1	0
137	Completing the Translation. <i>Oncologist</i> , 2020, 25, 183-185.	3.7	0
138	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0